Pfizer Inc (NYSE:PFE)’s traded shares stood at 6.56 million during the latest session, with the company’s beta value hitting 0.62. At the last check today, the stock’s price was $25.26, to imply an increase of 0.12% or $0.03 in intraday trading. The PFE share’s 52-week high remains $31.54, putting it -24.86% down since that peak but still an impressive 3.09% since price per share fell to its 52-week low of $24.48. The company has a valuation of $143.15B, with an average of 40.95 million shares in intraday trading volume over the past 10 days and average of 38.72 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Pfizer Inc (PFE), translating to a mean rating of 2.28. Of 16 analyst(s) looking at the stock, 1 analyst(s) give PFE a Sell rating. 1 of those analysts rate the stock as Overweight while 7 advise Hold as 7 recommend it as a Buy.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Pfizer Inc (NYSE:PFE) trade information
After registering a 0.12% upside in the latest session, Pfizer Inc (PFE) has traded red over the past five days. The 5-day price performance for the stock is -2.21%, and -9.75% over 30 days. With these gigs, the year-to-date price performance is -12.26%. Short interest in Pfizer Inc (NYSE:PFE) saw shorts transact 94.54 million shares and set a 2.07 days time to cover.
The extremes give us $30 and $36 for target low and target high price respectively. As such, PFE has been trading -42.52% off suggested target high and -18.76% from its likely low.
Pfizer Inc (PFE) estimates and forecasts
Looking at statistics comparing Pfizer Inc share performance against respective industry, we note that the company has outperformed competitors. Pfizer Inc (PFE) shares are -12.29% down over the last 6 months, with its year-to-date growth rate higher than industry average at 58.15% against 9.10%.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -27.43% for the past 5-year period. While 2024 is set for a 58.00% return in earnings, projections for the next 5 years are at 5.10% annually.
PFE Dividends
Pfizer Inc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Pfizer Inc has a forward dividend ratio of 1.68, with the share yield ticking at 6.65% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 4.28%.
Pfizer Inc (NYSE:PFE)’s Major holders
Pfizer Inc insiders hold 0.05% of total outstanding shares, with institutional holders owning 67.83% of the shares at 67.86% float percentage. In total, 67.83% institutions holds shares in the company, led by VANGUARD GROUP INC. As of 2024-06-30, the company held over 511.4 million shares (or 9.0402% of shares), all amounting to roughly $14.31 billion.
The next major institution holding the largest number of shares is BLACKROCK INC. with 424.38 million shares, or about 7.5018% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $11.87 billion.
